Mycoplasma Testing Market Worth $1.4 Billion By 2025 | CAGR: 14.1%: Grand View Research, Inc.

Monday, April 10, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

SAN FRANCISCO, April 10, 2017 /PRNewswire/ --

The global mycoplasma testing market

is expected to reach a value of USD 1.4 billion by 2025, according to a new report by Grand View Research, Inc. With growing R&D investments in the field of life sciences, the demand for mycoplasma testing products are
anticipated to rise in the near future. Huge opportunities in the life sciences segment are spurring the market growth. Hence, a large amount of investment is being made in the biotechnology and pharmaceutical industries with rising level of healthcare spending across the globe. This is expected to trigger high growth of mycoplasma testing market.

     (Logo: )

Investment in R&D activities by pharmaceutical and biotechnology companies is increasingly being supported by the government. Researches involving drug discovery and development, receive funding from the governmental bodies to a great extent. Moreover, governmental initiatives in the form of awareness campaigns for chronic diseases such as cancer are also encouraging research-based activities. Thus, the aforementioned factors are expected to drive the market growth.

Mycoplasma contamination of cell culture is a growing concern for most of the research scientists for decades. Mycoplasma infection arises majorly from laboratory workers as human mycoplasma contamination occurs at a faster rate. In order to combat further contamination, mycoplasma tests are being conducted, which is expected to increase the demand of the related products.

Browse full research report with TOC on "Mycoplasma Testing Market Analysis By Product, By Technology (PCR, ELISA, Direct Assay, Microbial Culture Techniques), By Application (Cell Line, Virus, & End of Production Cells Testing), By End-use, And Segment Forecasts, 2014 - 2025" at:

Further key findings from the report suggest: 

  • Peripheral bone densitometry is expected to exhibit lucrative CAGR owing to increasing adoption in wide array of clinical applications. The high penetration can be attributed to efficient peripheral fracture risk assessment, not achievable by other technologies
  • Clinics are anticipated to exhibit lucrative CAGR during the forecast period owing to advent of portable densitometers that are increasingly being preferred by clinicians due to associated benefits such as compact size, accuracy, and ease of transportation
  • In 2016, North America held a dominant share of the global bone densitometers market, as a consequence of increasing localized presence of prominent companies undertaking competitive sustainability strategies
  • Asia Pacific is anticipated to grow at an exponential CAGR due to unmet patient needs, continuous technological & infrastructural upgradation, and growing healthcare expenditure
  • Some key participants implement various competitive strategies, such as new product development & frequent product approvals, to maintain their position in the market
  • For instance, in October 2016, BeamMed launched neonatal bone growth assessment software for premature babies, which is compatible with most of the densitometer tools

Browse related reports by Grand View Research: 

  • Multi-Infarct Dementia Market -
  • Microbiology Culture Market -
  • Clinical Diagnostics Market -
  • Prokaryotic Expression Systems Market -

Grand View Research has segmented the mycoplasma testing market on the basis of product, technology, application, end-use, and region: 

  • Mycoplasma Testing Product Outlook (Revenue, USD Million, 2014 - 2025) 
    • Instruments
    • Kits & Reagents
      • PCR Assays
      • Nucleic Acid Detection Kits
      • Stains
      • Elimination Kits
      • Standards & Controls
      • Others
    • Services
  • Mycoplasma Testing Technology Outlook (Revenue, USD Million, 2014 - 2025) 
    • PCR
    • ELISA
    • Direct Assay
    • Indirect Assay
    • Microbial Culture Techniques
    • Enzymatic Methods
  • Mycoplasma Testing Application Outlook (Revenue, USD Million, 2014 - 2025) 
    • Cell Line Testing
    • Virus Testing
    • End of Production Cells Testing
    • Others
  • Mycoplasma Testing End-Use Outlook (Revenue, USD Million, 2014 - 2025) 
    • Academic Research Institutes
    • Cell Banks
    • Contract Research Organizations
    • Pharmaceutical & Biotechnology Companies
    • Others
  • Mycoplasma Testing Regional Outlook (Revenue, USD Million, 2014 - 2025) 
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • UK
    • Asia Pacific
      • Japan
      • China
      • India
    • Latin America
      • Brazil
      • Mexico
    • MEA
      • South Africa

Read Our Blog: Bone Densitometers: Tools for advanced metabolic bone disease assessment

About Grand View Research 

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc Phone: +1-415-349-0058 Toll Free: +1-888-202-9519 Email:


SOURCE Grand View Research, Inc.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store